Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of icaritin + lenvatinib + TACE for unresectable non-metastatic hepatocellular carcinoma
ChiCTR2300071811Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Icaritin and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
Icaritinlenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300071811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071811.